Semaglutide: research overview

The short version

Semaglutide is an engineered version of a hormone your gut makes after every meal — glucagon-like peptide-1 (GLP-1). The natural version lasts about two minutes; semaglutide is built to last roughly a week. It does that with two modifications: a chemical change at position 8 that blocks the enzyme that normally destroys GLP-1, and a fatty-acid arm that anchors it to blood protein albumin, slowing clearance through the kidneys.

In clinical trials, semaglutide has been studied in tens of thousands of people for type 2 diabetes, obesity, and established cardiovascular disease. The STEP 1 trial found a mean body-weight change of -14.9% over 68 weeks versus -2.4% with placebo in adults with overweight or obesity ^[4]. The SELECT trial in 17,604 adults with existing cardiovascular disease found a 20% relative reduction in major adverse cardiovascular events compared with placebo ^[3]. These are large, well-powered randomised controlled trials published in peer-reviewed journals.

Semaglutide is an FDA-approved prescription medicine. This page summarizes its published research. It is not a product listing, dosing guide, or medical recommendation.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing approximately 94% sequence homology with the native hormone. Two backbone substitutions confer protease resistance: the alanine at position 8 is replaced by alpha-aminoisobutyric acid (Aib), blocking dipeptidyl peptidase-4 (DPP-4) cleavage; position 34 lysine is replaced by arginine. The remaining lysine at position 26 is acylated with a C18 fatty di-acid via a spacer, driving reversible binding to serum albumin and extending the half-life to approximately one week.

It is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist, also called an incretin mimetic, in the same drug class as liraglutide, dulaglutide, and exenatide. Within that class, semaglutide's albumin-binding design is the structural basis for once-weekly dosing rather than daily or twice-daily injections.

Semaglutide is FDA-approved for multiple indications: type 2 diabetes mellitus, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and (as of 2025) metabolic dysfunction-associated steatohepatitis (MASH). It is available as both a once-weekly subcutaneous injection and a once-daily oral tablet.

How it works

Semaglutide activates GLP-1 receptors distributed across multiple tissues. The documented mechanism targets include:

• Pancreatic beta cells: GLP-1 receptor activation potentiates insulin secretion in a glucose-dependent fashion — the insulin signal is amplified only when blood glucose is elevated, reducing the risk of hypoglycaemia on semaglutide alone.
• Pancreatic alpha cells: glucagon secretion is suppressed, reducing the liver's glucose output between meals.
• Gastric smooth muscle and vagal afferents: gastric emptying is slowed, blunting post-meal glucose spikes and contributing to earlier satiety.
• Hypothalamic arcuate nucleus and brainstem: animal studies demonstrate that semaglutide reaches appetite-regulating circuits, activating anorexigenic POMC/CART neurons and inhibiting orexigenic NPY/AgRP neurons ^[6]. This central action is the primary mechanism of the weight reduction effect — food intake decreases; energy expenditure does not fall ^[6].
• Cardiovascular and renal GLP-1 receptors: pleiotropic effects that may underlie the trial-level cardiovascular and kidney-protective findings ^[2][3][7].

The weight-loss mechanism is primarily central appetite suppression, not metabolic acceleration. Rodent studies using fluorescence imaging confirm direct brainstem and hypothalamic access ^[6].

What the research shows

Weight management

In STEP 1 (n=1,961, adults with overweight or obesity without diabetes), once-weekly subcutaneous semaglutide produced a mean body-weight change of -14.9% from baseline to week 68 versus -2.4% with placebo — a treatment difference of approximately 12.4 percentage points ^[4].

In the head-to-head SURMOUNT-5 trial (n=751, adults with obesity without diabetes), semaglutide at maximum tolerated doses produced a mean weight loss of -13.7% over 72 weeks, compared with -20.2% for tirzepatide — a statistically significant difference (P<0.001) favouring tirzepatide ^[1].

Cardiovascular outcomes

SELECT (n=17,604, adults with preexisting cardiovascular disease and overweight/obesity but no diabetes) found that once-weekly semaglutide reduced the primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke: HR 0.80 (95% CI 0.72–0.90, P<0.001), a 20% relative risk reduction ^[3].

SUSTAIN-6 (n=3,297, type 2 diabetes at high cardiovascular risk) reported a primary MACE HR of 0.74 (95% CI 0.58–0.95), establishing cardiovascular noninferiority and superiority. The same trial noted a significantly higher rate of diabetic-retinopathy complications (HR 1.76; 95% CI 1.11–2.78), concentrated in patients with pre-existing retinopathy undergoing rapid glycaemic correction ^[7].

Kidney disease

The FLOW trial (n=3,533, type 2 diabetes with chronic kidney disease) found that semaglutide 1.0 mg once weekly reduced major kidney-disease events (kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death): HR 0.76 (95% CI 0.66–0.88), a 24% lower risk versus placebo ^[2].

Neural mechanism of weight loss

Rodent studies demonstrated that semaglutide lowers body weight by accessing the brainstem (area postrema), hypothalamic arcuate nucleus, and parabrachial nucleus, reducing food intake and modifying food preference without decreasing energy expenditure ^[6]. These central-nervous-system findings in animals support the appetite-circuit hypothesis for the weight effects seen in humans.

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence)

Accounts from people who have used semaglutide in research or clinical contexts describe a consistent pattern: the most frequently reported benefit is a dramatic quieting of food noise — the constant background mental chatter about eating, cravings, and the next meal. Reviewers describe feeling full on substantially smaller portions, with cravings for sweet, greasy, and high-fat foods dropping sharply or disappearing, sometimes within the first week or two. Weight loss — described as steady and substantial over months — is reported by the overwhelming majority. People with type 2 diabetes commonly describe markedly improved blood-sugar and HbA1c readings. An unexpected secondary observation reported by some users is reduced desire to drink alcohol. All of the above are anecdotal community reports, unverified, and are not clinical findings.

The most frequently reported adverse effects: nausea (the dominant complaint, described by roughly a third of users; peaks around dose increases, typically eases within a week or two); sulfur or egg burps (a distinctive complaint involving foul-smelling burps linked to slowed gastric emptying, reported as more common than official label frequencies suggest); constipation and/or diarrhea (both extremes reported, sometimes alternating); acid reflux; fatigue in the first days after injection; food aversions and altered taste sensitivity. A smaller subset reports hair shedding (typically appearing months after starting, attributed to the rate and magnitude of weight loss rather than a direct drug effect) and headaches or dizziness, often linked to inadequate hydration and caloric intake. All of the above are anecdotal, unverified, and are not clinical findings.

Safety cautions from the clinical literature

• Gastrointestinal intolerance during dose escalation: nausea, vomiting, diarrhea, and constipation are the dominant adverse effects in clinical trials and the leading cause of discontinuation. The safety review by Smits and Van Raalte (2021) reported nausea in roughly one-third of patients; events are predominantly mild-to-moderate and transient, concentrated around the titration period ^[5].
• Thyroid C-cell tumours / medullary thyroid carcinoma (boxed warning): GLP-1 receptor agonists carry a boxed warning derived from rodent studies. A dedicated human-evidence review found no clear human MTC signal established to date, but a personal or family history of medullary thyroid carcinoma or MEN-2 is treated as a contraindication ^[5].
• Acute pancreatitis (class warning): a recognised class caution; the safety review notes that pancreatic-cancer signals remain unconfirmed rather than demonstrated associations ^[5].
• Gallbladder and biliary disease (cholelithiasis): the safety review found an increased risk of cholelithiasis, attributed largely to the rate and magnitude of weight loss rather than a direct drug toxicity ^[5].
• Diabetic retinopathy with rapid glycaemic correction: SUSTAIN-6 found retinopathy-complication HR 1.76 (95% CI 1.11–2.78) in patients with pre-existing retinopathy undergoing rapid HbA1c reduction; monitoring is advised ^[7][5].
• Lean-mass loss: body-composition substudies from the STEP programme show a meaningful fraction of total weight lost is lean mass, raising sarcopenia concerns particularly in older adults.
• Weight regain after discontinuation: STEP 1 extension and STEP 4 data demonstrate substantial weight regain after stopping — a mean of approximately 11.6 percentage points within one year — framing this as a chronic rather than curative intervention.
• Pregnancy: contraindicated; the approximately one-week half-life means effectively complete clearance requires about five weeks after the last dose.

Where it fits

Semaglutide is the featured lead compound on this desk because it has the broadest and most mature evidence base of the incretin-based metabolic agents: a dedicated cardiovascular outcomes trial with 17,604 participants ^[3], a kidney-disease trial with 3,533 participants ^[2], and the STEP weight-management programme including a head-to-head comparison against tirzepatide ^[1][4]. Within the appetite-and-satiety framing of this hub, it represents the single-receptor (GLP-1R) approach — activating one incretin pathway with a highly optimised, long-acting ligand.

For a direct comparison with tirzepatide's dual-receptor approach, see the compare page. For the full list of sources cited on this page, see the references.